Difficult-to-treat resistance in gram-negative bacteremia at 173 US hospitals: Retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents

Clinical Infectious Diseases

Volumn 67, Issue 12, 2018, Pages 1803-1814

  Kadri, Sameer S ^a,b   Adjemian, Jennifer ^c,d   Lai, Yi Ling ^c   Spaulding, Alicen B ^c   Ricotta, Emily ^c   Rebecca Prevots, D ^c   Palmore, Tara N ^a   Rhee, Chanu ^e,f   Klompas, Michael ^e,f   Dekker, John P ^g   Powers, John H ^h   Suffredini, Anthony F ^a   Hooper, David C ^b   Fridkin, Scott ⁱ   Danner, Robert L ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d U S PUBLIC HEALTH SERVICE   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g NATIONAL INSTITUTES OF HEALTH   (United States)

^h FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

ⁱ CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Antimicrobial resistance; Gram negative bacteria; Mortality

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; CARBAPENEM DERIVATIVE; CEPHALOSPORIN; COLISTIN; GENTAMICIN; POLYMYXIN B; QUINOLONE DERIVATIVE; TIGECYCLINE; ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; AMINOGLYCOSIDE RESISTANCE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; COHORT ANALYSIS; ENTEROBACTER; ESCHERICHIA COLI; FEMALE; GRAM NEGATIVE SEPSIS; HUMAN; KLEBSIELLA; MALE; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; URBAN AREA; ADOLESCENT; ADULT; AGED; BACTEREMIA; DRUG EFFECT; FACTUAL DATABASE; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; HOSPITAL; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; MULTIDRUG RESISTANCE; PROGNOSIS; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; CARBAPENEMS; DATABASES, FACTUAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; FLUOROQUINOLONES; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HOSPITALS; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PREVALENCE; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 85052698503     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciy378     Document Type: Article

References (31)

1. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. Available at: http://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf. Accessed 20 October 2017 .
2. O'Neill J. Antimicrobial resistance: tackling a crisis for the health and wealth of nations. In: Review on antimicrobial resistance. Antimicrobial resistance: tackling a crisis for the health and wealth of nations. 2014. Available at: https://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20 the%20health%20and%20wealth%20of%20nations_1.pdf. Accessed 20 June 2018.
3. Nordmann P, Naas T, Poirel L. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 2011; 17:1791-8.
4. CTX-M on a novel IncF plasmid: first report of mcr-1 in the United States. Antimicrob Agents Chemother 2016; 60:4420-1.
5. Fridkin SK, Cleveland AA, See I, Lynfield R. Emerging infections program as surveillance for antimicrobial drug resistance. Emerg Infect Dis 2015; 21:1578-81.
6. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18:268-81.
7. Zilberberg MD, Nathanson BH, Sulham K, Fan W, Shorr AF. Multidrug resistance, inappropriate empiric therapy, and hospital mortality in Acinetobacter baumannii pneumonia and sepsis. Crit Care 2016; 20:221.
8. Zeng ZR, Wang WP, Huang M, Shi LN, Wang Y, Shao HF. Mechanisms of carbapenem resistance in cephalosporin-susceptible Pseudomonas aeruginosa in China. Diagn Microbiol Infect Dis 2014; 78:268-70.
9. Dimopoulos G, Koulenti D, Tabah A, et al. Bloodstream infections in ICU with increased resistance: epidemiology and outcomes. Minerva Anestesiol 2015; 81:405-18.
10. Burnham JP, Lane MA, Kollef MH. Impact of sepsis classification and multidrug-resistance status on outcome among patients treated with appropriate therapy. Crit Care Med 2015; 43:1580-6.
11. Tabah A, Koulenti D, Laupland K, et al. Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: the EUROBACT International Cohort Study. Intensive Care Med 2012; 38:1930-45.
12. Satlin MJ, Jenkins SG, Walsh TJ. The global challenge of carbapenem-resistant Enterobacteriaceae in transplant recipients and patients with hematologic malignancies. Clin Infect Dis 2014; 58:1274-83.
13. Vicari G, Bauer SR, Neuner EA, Lam SW. Association between colistin dose and microbiologic outcomes in patients with multidrug-resistant gram-negative bacteremia. Clin Infect Dis 2013; 56:398-404.
14. Prasad P, Sun J, Danner RL, Natanson C. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis 2012; 54:1699-709.
15. Cohen AL, Calfee D, Fridkin SK, et al; Society for Healthcare Epidemiology of America and the Healthcare Infection Control Practices Advisory Committee. Recommendations for metrics for multidrug-resistant organisms in healthcare settings:SHEA/HICPACpositionpaper.InfectControlHospEpidemiol2008;29:901-13.
16. Robert Koch Institute. Hygiene measures for infection or colonization with multidrug-resistant gram-negative bacilli. Commission recommendation for hospital hygiene and infection prevention (KRINKO) at the Robert Koch Institute (RKI) [in German]. Bundesgesundheitsblatt 2012; 55:1311-54.
17. National Healthcare Safety Network, Centers for Disease Control and Prevention. Antibiotic resistance patient safety atlas: phenotypic definitions. 2016. Available at: https://www.cdc.gov/hai/pdfs/patient-safety-atlas/AR-Patient-Safety-AtlasPhenotype-Definitions.pdf. Accessed 20 June 2018.
18. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005; 43:1130-9.
19. Baram D, Daroowalla F, Garcia R, et al. Use of the All Patient Refined-Diagnosis Related Group (APR-DRG) risk of mortality score as a severity adjustor in the medical ICU. Clin Med Circ Respirat Pulm Med 2008; 2:19-25.
20. The White House. National Action Plan for Combating Antibiotic-resistant Bacteria. Available at: https://obamawhitehouse.archives.gov/sites/default/files/docs/national_action_plan_for_combating_antibotic-resistant_bacteria.pdf. Accessed 20 June 2018.
21. Guh AY, Bulens SN, Mu Y, et al. Epidemiology of carbapenem-resistant Enterobacteriaceae in 7 US communities, 2012-2013. JAMA 2015; 314:1479-87.
22. Wong PH, von Krosigk M, Roscoe DL, Lau TT, Yousefi M, Bowie WR. Antimicrobial co-resistance patterns of gram-negative bacilli isolated from bloodstream infections: a longitudinal epidemiological study from 2002-2011. BMC Infect Dis 2014; 14:393.
23. Leibovici L, Shraga I, Drucker M, Konigsberger H, Samra Z, Pitlik SD. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med 1998; 244:379-86.
24. Roberts RR, Hota B, Ahmad I, et al. Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. Clin Infect Dis 2009; 49:1175-84.
25. Cosgrove SE. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clin Infect Dis 2006; 42:S82-9.
26. Lambert ML, Suetens C, Savey A, et al. Clinical outcomes of health-care-associated infections and antimicrobial resistance in patients admitted to European intensive-care units: a cohort study. Lancet Infect Dis 2011; 11:30-8.
27. Falagas ME, Tansarli GS, Karageorgopoulos DE, Vardakas KZ. Deaths attributable to carbapenem-resistant Enterobacteriaceae infections. Emerg Infect Dis 2014; 20:1170-5.
28. Lye DC, Earnest A, Ling ML, et al. The impact of multidrug resistance in healthcare-associated and nosocomial gram-negative bacteraemia on mortality and length of stay: cohort study. Clin Microbiol Infect 2012; 18:502-8.
29. Cosgrove SE, Qi Y, Kaye KS, Harbarth S, Karchmer AW, Carmeli Y. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol 2005; 26:166-74.
30. Blot S, Depuydt P, Vandewoude K, De Bacquer D. Measuring the impact of multidrug resistance in nosocomial infection. Curr Opin Infect Dis 2007; 20:391-6.
31. World Health Organization. Global tuberculosis report, 2017. Available at: http://www.who.int/tb/publications/global_report/en/. Accessed 20 June 2018.